- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03306875
Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis
This study aims to apply baseline MRI and neuropsychological measures to predict patient responses to behavioral cognitive rehabilitation. Training will take place over 12 weeks, 1 hour per day, 5 days per week.
The investigator hypothesizes the following:
[1a] The investigator expects that individuals with low baseline Conscientiousness will experience a lower magnitude of overall cognitive improvement following rehabilitation
- b] The investigator expects the impact of Conscientiousness on fidelity of rehabilitation will in part be moderated by individual differences in program adherence and executive function
- a] The investigator expects that individual differences in structural and functional connectome disturbances will in part explain differences in participant responses to cognitive rehabilitation.
This study will also serve to supplement the sample of participants for the current IRB approved study ((IRB: 603069, Title: A case-control, 5-year follow-up study of cardiovascular, environmental and genetic risk factors for disease progression in patients with multiple sclerosis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The participant will be asked to make a total of two (2) visits, approximately 90 days apart. Each visit will involve: neuro-performance testing, and self-report questionnaires. Each study visit is expected to take approximately 1-2 hours. Between the two visits, the participant will be asked to complete a 12 week, computer-based cognitive training program. This includes 1 hour of training each day for 5 days each week.
On Visit 1, the participants will undergo a full battery of neuro-performance tasks including tests and questionnaires that will measure their memory, thinking speed, fatigue, and personality. This visit is expected to take approximately 1-2 hours. The participants will be also asked to have a close friend or family member to complete similar surveys. A self-addressed envelope containing these questionnaires will be provided to take home with them. The participant will need to pass it onto a close friend or family member to be completed and mailed back.
In addition, the participant will be asked to take part in the 12 week computerized cognitive training program. This can be done at home, or anywhere the participant has access to a computer and internet. This cognitive training has been shown to improve cognitive performance in people with multiple sclerosis. The training involves a variety of interactive exercises which adapt to their abilities. The participants will need complete 1 hour of training each day, for 5 days each week.
At 90 days, the participant will return for the 1-2 hours' follow-up visit where they will complete the same cognitive testing and questionnaires which they had completed during visit 1.
All study visits will take place at Buffalo General Hospital. All of the procedures described above will be performed by a trained member of the research team as part of the research study.
If an individual is ineligible for participation, their screening information will be discarded (i.e., shredded). If participants are deemed eligible (either in person or over the phone), they will be scheduled to come in to the hospital for neuropsychological testing. Written consent will be obtained prior to administration of tests. As part of the consent process, participants will be asked for permission to use any data collected as part of the screening process as well.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14203
- Jacobs Comprehensive Multiple Sclerosis Treatment and Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For all subjects:
- males and females above age 18
- fluent in English
- education >9 years
Additional inclusion criteria for MS patients are as follows:
- Clinically definite MS diagnosis
- Expanded Disability Status Scale (EDSS) ≤ 6.5
- MS patients must be relapse-free and stable from the time of their MRI acquired for the CEG-MS study
- Willing and able to comply with the study procedures for the duration of the trial
Exclusion Criteria:
- history of serious medical or psychiatric illness (other than MS in the patient group) that may affect cognitive functioning
- color-blindness
- history of developmental disability
- past or current alcohol or substance dependence
- History of major depressive disorder, bipolar disorder, or psychotic disorder predating the onset of MS
- History of traumatic brain injury as defined by trauma causing loss of consciousness or transient post-traumatic or retrograde amnesia exceeding 5 min
- Other pathology related to MRI abnormalities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cognitive Training
Individuals will take part in a computer-based cognitive training program.
The program is aimed at building attention, processing speed, memory, and executive function.
|
Individuals will take part in a computer-based cognitive training program.
The program is aimed at building attention, processing speed, memory, and executive function.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of Conscientiousness on Cognitive Training Outcomes
Time Frame: This outcome will be measured according to changes from baseline cognition to follow-up measures, 12 weeks later (following cognitive rehabilitation)
|
The investigator expects baseline Conscientiousness to correlate positively with cognitive gains following rehabilitation. Conscientiousness will be measured using the NEO-Five Factor Inventory (NEOFFI). All scores for personality testing will be converted to age-corrected t-scores for final analysis. These are therefore standardized values without units. |
This outcome will be measured according to changes from baseline cognition to follow-up measures, 12 weeks later (following cognitive rehabilitation)
|
|
Cognitive Training Outcomes
Time Frame: This outcome will be measured according to changes from baseline cognition to follow-up measures, 12 weeks later (following cognitive rehabilitation)
|
Cognitive gains will be measured according to differences between baseline and followup testing for the following tests of cognition.
All scores for cognitive testing will be converted to age-corrected t-scores for final analysis. These are therefore standardized values without units. |
This outcome will be measured according to changes from baseline cognition to follow-up measures, 12 weeks later (following cognitive rehabilitation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Moderating role of executive function
Time Frame: 12 weeks, as above
|
The investigator will assess whether baseline scores of executive function moderate the impact of Conscientiousness on cognitive training. Executive function will be reported according to scores on the following tests.
|
12 weeks, as above
|
|
Moderating role of program adherence
Time Frame: 12 weeks, as above
|
The investigator will assess whether daily program adherence is a moderates the impact of Conscientiousness on cognitive training.
Daily program adherence will be measured according to days and hours spent on cognitive training exercises.
|
12 weeks, as above
|
|
Impact of baseline brain connectivity on cognitive rehabilitation outcomes
Time Frame: 12 weeks, as above
|
The investigator will assess whether individual differences in structural and functional connectome disturbances in part explain differences in participant responses to cognitive rehabilitation. In order to address outcome number 5, white matter tract disruption will be characterized in order to determine how structural networks are impacted by white matter lesions. Tract disruption will be reported as the proportion of tracts normally connecting pairs of gray matter brain regions which are disrupted by lesions. These will therefore be reported as percent values. |
12 weeks, as above
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00001899
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Cognitive Training
-
Science and Research Centre KoperAlbert Einstein College of Medicine; University of Primorska; Vrije Universiteit...CompletedEffects of Cognitive Intervention on Cognition, Mobility and Brain Electrocortical Activity (GIBKOP)Cognitive Impairment | Aging | Cognitive Decline | Motor Coordination or FunctionSlovenia
-
Hospital de Clinicas de Porto AlegreYale UniversityUnknownAttention-deficit/Hyperactivity Disorder.Brazil
-
Universidade Federal do Rio de JaneiroUnknown
-
Chang Gung Memorial HospitalRecruitingVirtual Reality | Community-dwelling ElderlyTaiwan
-
Fanfan ZhengEnrolling by invitationDiabetes Mellitus, Type 2 | Aging | CognitionChina
-
Xuanwu Hospital, BeijingRecruitingMild Cognitive ImpairmentChina
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Chiang Mai UniversityCompletedMild Cognitive ImpairmentThailand
-
Chang Gung Memorial HospitalRecruitingMCI | SCD | Virtual RealityTaiwan
-
University of California, San FranciscoCompletedSchizophrenia | PsychosisUnited States